We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-19.32%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$114M
AUM Growth
-$57.2M
Cap. Flow
-$13.7M
Cap. Flow %
-12.06%
Top 10 Hldgs %
77.21%
Holding
33
New
2
Increased
7
Reduced
13
Closed
11

Top Buys

1
NEOS
Neos Therapeutics, Inc
NEOS
+$11.2M
2
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
+$7.37M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.39M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$3.23M
5
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
+$2.81M

Top Sells

1
MLNT
Melinta Therapeutics, Inc. Common Stock
MLNT
+$7.74M
2
AMRN
Amarin Corp
AMRN
+$7.29M
3
BSTC
BioSpecifics Technologies Corp.
BSTC
+$4.05M
4
KALV
KalVista Pharmaceuticals
KALV
+$3.05M
5
CDTX
Cidara Therapeutics
CDTX
+$2.89M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
1
Amarin Corp
AMRN
$292M
$15M 13.15%
55,000
-20,000
-27% -$7.29M
BDSI
2
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$14.7M 12.94%
3,981,867
-329,236
-8% -$1.16M
BSTC
3
DELISTED
BioSpecifics Technologies Corp.
BSTC
$13.2M 11.57%
217,395
-67,864
-24% -$4.05M
CPIX icon
4
Cumberland Pharmaceuticals
CPIX
$102M
$7.92M 6.96%
1,313,429
+95,028
+8% +$569K
APEN
5
DELISTED
Apollo Endosurgery, Inc.
APEN
$7.54M 6.62%
2,185,426
-392,570
-15% -$1.94M
NEOS
6
DELISTED
Neos Therapeutics, Inc
NEOS
$6.95M 6.1%
4,210,153
+3,982,234
+1,747% +$11.2M
HTGM
7
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$6.8M 5.97%
14,866
+11,890
+400% +$7.37M
VNDA icon
8
Vanda Pharmaceuticals
VNDA
$327M
$5.77M 5.07%
220,848
-103,752
-32% -$2.44M
OPNT
9
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$5.17M 4.54%
357,960
+172,073
+93% +$2.81M
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.89M 4.29%
4,072,301
+1,747,519
+75% +$3.39M
ALIM
11
DELISTED
Alimera Sciences
ALIM
$4.7M 4.13%
436,518
-29,339
-6% -$428K
FOMX
12
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.64M 4.08%
1,293,177
+742,099
+135% +$3.23M
CTIC
13
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$4.2M 3.69%
5,726,579
+424,516
+8% +$697K
VIVE
14
DELISTED
VIVEVE MED INC
VIVE
$3.59M 3.15%
3,418
-432
-11% -$1.04M
OXFD
15
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.84M 2.5%
222,321
-3,556
-2% -$53.9K
AFMD
16
DELISTED
Affimed
AFMD
$2.22M 1.95%
+71,408
New +$2.66M
CORV
17
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$1.06M 0.93%
424,101
-474,056
-53% -$1.58M
CEMI
18
DELISTED
Chembio diagnostics, Inc.
CEMI
$832K 0.73%
+147,011
New +$1.08M
ATEC icon
19
Alphatec Holdings
ATEC
$1.31B
$775K 0.68%
338,278
-413,478
-55% -$1.16M
MTEM
20
DELISTED
Molecular Templates, Inc.
MTEM
$463K 0.41%
7,647
-17,573
-70% -$1.23M
NVLN
21
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$447K 0.39%
531,662
-1,197,225
-69% -$1.35M
ATXS
22
DELISTED
Astria Therapeutics
ATXS
$182K 0.16%
6,948
-29,155
-81% -$1.1M
ALDX icon
23
Aldeyra Therapeutics
ALDX
$102M
– –
-145,000
Closed -$2M
CDTX
24
DELISTED
Cidara Therapeutics
CDTX
– –
-32,807
Closed -$2.89M
KALV
25
DELISTED
KalVista Pharmaceuticals
KALV
– –
-138,100
Closed -$3.05M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Stonepine Capital Management held 33 positions worth $114M, down 33% from $171M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Stonepine Capital Management withdrew a net $13.7M in Q4 2018, closing 11 positions and reducing 13 holdings. Its most notable exit was Melinta Therapeutics, Inc. Common Stock, an estimated $7.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Affimed worth $2.22M.

  • Stonepine Capital Management's largest Q4 2018 buy was Affimed: 71,408 shares worth $2.22M.
  • Stonepine Capital Management added most to Neos Therapeutics, Inc in Q4 2018, an estimated $11.2M increase.
  • Stonepine Capital Management's biggest Q4 2018 reduction was Amarin Corp, cutting an estimated $7.29M.
  • Stonepine Capital Management fully exited Melinta Therapeutics, Inc. Common Stock in Q4 2018, selling an estimated $7.74M.
  • Stonepine Capital Management's ten largest holdings make up 77% of its $114M portfolio in Q4 2018.
  • Stonepine Capital Management opened 2 new positions and closed 11 in Q4 2018.
  • Stonepine Capital Management's portfolio value fell 33% quarter-over-quarter to $114M.

Based on Stonepine Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.